Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension

Hypertension Research

Volumn 35, Issue 1, 2012, Pages 28-33

  Zhu, Jun Ren ^a   Sun, Ning Ling ^b   Yang, Kan ^c   Hu, Jian ^d   Xu, Geng ^e   Hong, Huashan ^f   Wang, Ruonan ^g   Tu, Ying Mei ^g   Ritter, Shannon ^h   Keefe, Deborah ^h  

^a FUDAN UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

^e ZHEJIANG UNIVERSITY   (China)

^f FUJIAN MEDICAL UNIVERSITY   (China)

^g Beijing Baiao Pharmaceuticals Co Ltd   (China)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aliskiren; Asian; cough; ramipril

Indexed keywords

ALISKIREN; PLACEBO; RAMIPRIL;

ADULT; AGED; ARTICLE; ASIAN; BLOOD PRESSURE REGULATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RAMIPRIL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84855433634     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.150     Document Type: Article

References (24)

1. Singh RB, Suh IL, Singh VP, Chaithiraphan S, Laothavorn P, Sy RG, Babilonia NA, Rahman AR, Sheikh S, Tomlinson B, Sarraf-Zadigan N. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 2000; 14: 749-763.
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
3. Whelton PK. Hypertension curriculum review: epidemiology and the prevention of hypertension. J Clin Hypertens (Greenwich) 2004; 6: 636-642.
4. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49: 69-75. (Pubitemid 46360343)
5. Writing group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension. Chin J Cardiol 2011; 39: 579-616. [Article in Chinese].
6. Fujita T, Wu Z, Park J-B, Chen M-F. Briefings on JHS, CHS, KHS and THS guidelines and their difference from JNC VII and ESC/ESH. Int J Clin Pract 2006; 60(Suppl 150): 3-7.
7. Aekplakorn W, Abbott-Klafter J, Khonputsa P, Tatsanavivat P, Chongsuvivatwong V, Chariyalertsak S, Sangwatanarojg S, Tiptaradolh S, Limb SS. Prevalence and management of prehypertension and hypertension by geographic regions of Thailand: the Third National Health Examination Survey, 2004. J Hypertens 2008; 26: 191-198.
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153. (Pubitemid 30051645)
9. Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res 2006; 98: 887-896.
10. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 169S-173S. (Pubitemid 43265218)
11. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005. (Pubitemid 46206586)
12. Chrysant SG. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. Expert Rev Cardiovasc Ther 2008; 6: 305-314.
13. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1-E8.
14. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143. (Pubitemid 37549068)
15. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018. (Pubitemid 40354519)
16. Oh BH, Mitchell J, Herron JR, Chung J, Khan M Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163. (Pubitemid 46400330)
17. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hypertens Res 2009; 32: 169-175.
18. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417-425.
19. Wu N, Zhu J, Chen K. Tolerability of ramipril 10mg/day in high-risk cardiovascular Chinese patients. Clin Drug Invest 2002; 22: 771-781. (Pubitemid 35388186)
20. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram GH, Fang H, Satlin A. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-198. (Pubitemid 351166266)
21. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-599.
22. Chan WK, Chan TY, Luk WK, Leung VK, Li TH, Critchley JA. A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1993; 44: 299-300. (Pubitemid 23096163)
23. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40: 141-144.
24. Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B2 receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 2000; 36: 127-131. (Pubitemid 30602164)